These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 25682970)

  • 21. mTOR inhibitors and autosomal dominant polycystic kidney disease.
    Grantham JJ; Bennett WM; Perrone RD
    N Engl J Med; 2011 Jan; 364(3):286-7; author reply 287-9. PubMed ID: 21247328
    [No Abstract]   [Full Text] [Related]  

  • 22. mTOR inhibitors and autosomal dominant polycystic kidney disease.
    Levey AS; Stevens LA
    N Engl J Med; 2011 Jan; 364(3):287; author reply 287-9. PubMed ID: 21247327
    [No Abstract]   [Full Text] [Related]  

  • 23. Polycystic kidney disease: a 2011 update.
    Steinman TI
    Curr Opin Nephrol Hypertens; 2012 Mar; 21(2):189-94. PubMed ID: 22274800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. mTOR inhibitors and autosomal dominant polycystic kidney disease.
    Braun WE
    N Engl J Med; 2011 Jan; 364(3):287; author reply 287-8. PubMed ID: 21247326
    [No Abstract]   [Full Text] [Related]  

  • 25. KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Pharmacological Management.
    Mallett A; Lee VW; Mai J; Lopez-Vargas P; Rangan GK
    Semin Nephrol; 2015 Nov; 35(6):582-589.e17. PubMed ID: 26718162
    [No Abstract]   [Full Text] [Related]  

  • 26. Long-term treatment with mammalian target of rapamycin inhibitor does not benefit patients with autosomal dominant polycystic kidney disease: a meta-analysis.
    Xue C; Dai B; Mei C
    Nephron Clin Pract; 2013; 124(1-2):10-6. PubMed ID: 24022660
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Optimal care of autosomal dominant polycystic kidney disease patients.
    Schrier RW
    Nephrology (Carlton); 2006 Apr; 11(2):124-30. PubMed ID: 16669974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Better understanding of ADPKD results in potential new treatment options: ready for the cure?
    Meijer E; de Jong PE; Peters DJ; Gansevoort RT
    J Nephrol; 2008; 21(2):133-8. PubMed ID: 18446706
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatic and renal manifestations in autosomal dominant polycystic kidney disease: a dichotomy of two ends of a spectrum.
    van Gulick JJ; Gevers TJ; van Keimpema L; Drenth JP
    Neth J Med; 2011 Sep; 69(9):367-71. PubMed ID: 21978978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical management of autosomal dominant polycystic kidney disease.
    Bennett WM; Elzinga LW
    Kidney Int Suppl; 1993 Jul; 42():S74-9. PubMed ID: 8361135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. mTOR inhibitors in polycystic kidney disease.
    Watnick T; Germino GG
    N Engl J Med; 2010 Aug; 363(9):879-81. PubMed ID: 20581393
    [No Abstract]   [Full Text] [Related]  

  • 32. Mechanisms and management of hypertension in autosomal dominant polycystic kidney disease.
    Rahbari-Oskoui F; Williams O; Chapman A
    Nephrol Dial Transplant; 2014 Dec; 29(12):2194-201. PubMed ID: 24463189
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autosomal dominant polycystic kidney disease and pain - a review of the disease from aetiology, evaluation, past surgical treatment options to current practice.
    Badani KK; Hemal AK; Menon M
    J Postgrad Med; 2004; 50(3):222-6. PubMed ID: 15377813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Do mTOR inhibitors still have a future in ADPKD?
    Perico N; Remuzzi G
    Nat Rev Nephrol; 2010 Dec; 6(12):696-8. PubMed ID: 21109768
    [No Abstract]   [Full Text] [Related]  

  • 35. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
    Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
    Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review of tolvaptan for autosomal dominant polycystic kidney disease.
    Baur BP; Meaney CJ
    Pharmacotherapy; 2014 Jun; 34(6):605-16. PubMed ID: 24706579
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Autosomal dominant polycystic kidney disease].
    Horie S
    Nihon Jinzo Gakkai Shi; 2011; 53(1):6-9. PubMed ID: 21370570
    [No Abstract]   [Full Text] [Related]  

  • 38. In vitro delivery of mTOR inhibitors by kidney-targeted micelles for autosomal dominant polycystic kidney disease.
    Cox A; Tung M; Li H; Hallows KR; Chung EJ
    SLAS Technol; 2023 Aug; 28(4):223-229. PubMed ID: 36804177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects.
    Chang MY; Ong AC
    Nephron Clin Pract; 2012; 120(1):c25-34; discussion c35. PubMed ID: 22205396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Trials and a View Toward the Future of ADPKD.
    Kim H; Hwang YH
    Adv Exp Med Biol; 2016; 933():105-121. PubMed ID: 27730438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.